Thrombosis and Coagulopathy in COVID-19.

Szczegóły
Abstrakt

Tytuł:: Thrombosis and Coagulopathy in COVID-19.
Autorzy:: Gómez-Mesa JE
Galindo-Coral S
Montes MC
Muñoz Martin AJ
Źródło:: Current problems in cardiology [Curr Probl Cardiol] 2021 Mar; Vol. 46 (3), pp. 100742. Date of Electronic Publication: 2020 Nov 02.
Typ publikacji:: Journal Article; Review
Język:: English
Imprint Name(s):: Publication: [Amsterdam] : Elsevier
Original Publication: Chicago, Year Book Medical Publishers.
MeSH Terms:: Pandemics*
SARS-CoV-2*
Blood Coagulation Disorders/*etiology
COVID-19/*complications
Blood Coagulation Disorders/epidemiology ; COVID-19/epidemiology ; Global Health ; Humans ; Incidence ; Thrombosis/epidemiology ; Thrombosis/etiology
References:: Blood Adv. 2018 Nov 27;2(22):3198-3225. (PMID: 30482763)
Adv Pharmacol Sci. 2015;2015:507151. (PMID: 26064103)
CMAJ. 2020 May 25;192(21):E583. (PMID: 32357997)
J Thromb Haemost. 2020 May;18(5):1020-1022. (PMID: 32239799)
JAMA. 2020 Apr 28;323(16):1612-1614. (PMID: 32191259)
J Thromb Haemost. 2020 Jun;18(6):1324-1329. (PMID: 32306492)
Monaldi Arch Chest Dis. 2020 May 19;90(2):. (PMID: 32425013)
Blood. 2020 Jun 4;135(23):2033-2040. (PMID: 32339221)
J Thromb Haemost. 2020 May;18(5):1023-1026. (PMID: 32338827)
Thromb Res. 2020 Jul;191:9-14. (PMID: 32353746)
J Thromb Haemost. 2020 Jul;18(7):1752-1755. (PMID: 32267998)
J Thromb Haemost. 2020 Aug;18(8):1995-2002. (PMID: 32369666)
Rev Esp Cardiol. 2020 Sep;73(9):749-757. (PMID: 32327870)
J Thromb Haemost. 2020 Aug;18(8):2073-2075. (PMID: 32408391)
N Engl J Med. 2020 Apr 30;382(18):1708-1720. (PMID: 32109013)
Blood Transfus. 2020 May;18(3):167-169. (PMID: 32281926)
Lancet. 2020 Mar 28;395(10229):1054-1062. (PMID: 32171076)
J Thromb Haemost. 2020 Jun;18(6):1421-1424. (PMID: 32271988)
China CDC Wkly. 2020 Feb 21;2(8):113-122. (PMID: 34594836)
Thromb Res. 2020 Jul;191:145-147. (PMID: 32291094)
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973. (PMID: 32311448)
J Thromb Haemost. 2020 Aug;18(8):1859-1865. (PMID: 32459046)
Lancet Haematol. 2020 Jun;7(6):e438-e440. (PMID: 32407672)
J Thromb Haemost. 2020 May;18(5):1094-1099. (PMID: 32220112)
Mil Med Res. 2020 Apr 20;7(1):19. (PMID: 32307014)
Entry Date(s):: Date Created: 20201127 Date Completed: 20210217 Latest Revision: 20211015
Update Code:: 20240105
PubMed Central ID:: PMC7605852
DOI:: 10.1016/j.cpcardiol.2020.100742
PMID:: 33243440
: Czasopismo naukowe

Full Text Finder

Since December 2019, an outbreak of coronavirus disease 2019 (COVID-19) which initially occurred in the city of Wuhan, located in China's Hubei province, spread around the world and on March 11, 2020, the World Health Organization declared the new Coronavirus disease 2019 (COVID-19) as a pandemic. The presence of comorbidities (eg, cardiovascular disease, obesity), Sepsis Induced Coagulopathy score >4, elevation of D-dimer (>6 times the normal value), C-reactive protein, troponins and other disseminated intravascular coagulation markers; is associated to a worse prognosis in hospitalized patients with severe COVD-19, reaching a hospital mortality of 42%. Initial anticoagulant treatment with low molecular weight heparin has been shown to reduce mortality by 48% at 7 days and 37% at 28 days and achieve a significant improvement in the arterial oxygen pressure/inspired fraction of O2 (PaO2/FiO2) by mitigating the formation of microthrombi and associated pulmonary coagulopathy.
(Copyright © 2020 Elsevier Inc. All rights reserved.)

Informacja